论文部分内容阅读
应用流式细胞计(FCM)研究了经抗癌药物米托蒽醌(DHAD)和钙拮抗剂(VP)单独或联合处理的人唾液腺腺样囊性癌 ACC—2细胞的周期运行情况。发现:VP 在20μg/ml浓度范围内对ACC—2细胞增殖周期无明显影响。DHAD 使细胞阻滞在 G_2M 期,并呈剂量依赖性;当剂量一定时,随时间延长,对G_2M 期阻断作用减轻,细胞周期运行有恢复趋向。DHAD 佐以 VP 则明显增强对 ACC—2细胞 G_2M 期的阻断作用。本实验结果为阐明 VP 增强 DHAD 抗癌作用的机制提供了依据。
Flow cytometry (FCM) was used to investigate the cycle behavior of human salivary adenoid cystic carcinoma ACC-2 cells treated with anticancer drug mitoxin (DHAD) and calcium antagonist (VP) alone or in combination. It was found that VP had no significant effect on the proliferation cycle of ACC-2 cells at a concentration of 20 μg/ml. DHAD blocked cells in the G 2 M phase in a dose-dependent manner. When the dose was fixed, the blocking effect on the G 2 M phase was alleviated and the cell cycle was restored after the time was prolonged. DHAD combined with VP markedly enhanced the blocking effect on G2M phase of ACC-2 cells. The results of this experiment provide a basis for elucidating the mechanism by which VP enhances the anticancer effect of DHAD.